Pulmonary Sclerosing Hemangioma with Pulmonary Metastasis

Komatsu, Teruya; Fukuse, Tatsuo; Wada, Hiroo; Sakurai, T

doi:10.1055/s-2005-872976

Cited by 32 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 This tumor is generally regarded as benign but rare cases involving lymph node metastasis [3][4][5][6][7] or multifocal lesions [8][9][10] have been reported. However, there have been no reports of pulmonary SH with pleural dissemination.…”

Section: Introductionmentioning

confidence: 99%

Pulmonary sclerosing hemangioma with pleural dissemination: Report of a case

et al. 2011

View full text Add to dashboard Cite

Pulmonary sclerosing hemangioma is relatively rare and is usually considered a benign tumor. There have been no reports of pulmonary sclerosing hemangioma with pleural dissemination. This report presents an extremely rare case of pulmonary sclerosing hemangioma with pulmonary dissemination. A 57-year-old woman was found to have an abnormal shadow in the right lower lung field on chest X-ray. Chest computed tomography (CT) indicated a 2.5-cm mass in the right lower lobe. A bronchoscopic biopsy failed to identify malignant cells, which led to the patient undergoing an excisional lung biopsy. Intraoperative findings showed a tumor in the right lower lobe with multiple small nodules in the pleura. The pathological findings revealed that the tumor was sclerosing hemangioma with pleural dissemination. Annual follow-up CT showed irregular pleural thickness, which suggested progressive dissemination 3 years after the operation. Although pulmonary sclerosing hemangioma is regarded as a benign tumor, the potential for malignancy may be a consideration in this setting.

show abstract

Section: Introductionmentioning

confidence: 99%

Pulmonary sclerosing hemangioma with pleural dissemination: Report of a case

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In addition, PSH may be low-grade malignancy, since cases of lymph node and lung metastases have been reported. Thus, FDG PET/CT could be useful for the differential diagnosis of low-grade malignancy of PSH, particularly when the SUVmax of PSH exceeds 2.5, or when lymph node and lung metastases are displayed on PET/CT images (9)(10)(11)(12)(13)(14), which would be of great assistance in the clinical treatment.…”

Section: Discussionmentioning

confidence: 99%

“…However, a few studies have suggested that certain benign pulmonary tumors, such as PSH, may be low-grade malignancies, since cases of lymph node and lung metastases have been reported (9)(10)(11)(12)(13)(14), or that the malignant transformation of lung benign tumors may be possible, such as the transformation of pulmonary hamartoma into adenocarcinoma, sarcoma or squamous cell carcinoma (15)(16)(17). Thus, it is also important to compare and analyze the characteristics of 18 F-FDG PET/CT in benign lung tumors and to evaluate their metabolic activities to choose the proper clinical management.…”

Section: Introductionmentioning

confidence: 99%

18F‑FDG PET/CT characteristics of pulmonary sclerosing hemangioma vs. pulmonary hamartoma

et al. 2018

View full text Add to dashboard Cite

Abstract. The radiological features of pulmonary sclerosing hemangioma (PSH) and pulmonary hamartoma are poorly specified. Thus, the present study aimed to compare and analyze the characteristics of fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) in PSH versus pulmonary hamartoma.18 F-FDG PET/CT characteristic findings of 12 patients with PSH and 14 patients with pulmonary hamartoma were retrospectively reviewed. A total of 12 lesions were detected from the 12 patients with PSH, of which 3 masses exhibited calcification. The mean diameter and standardized maximum uptake value (SUVmax) were 1.9±0.7 cm and 2.6±1.0, respectively, and there was no significant correlation between the lesion size and SUVmax (P>0.05). For the 14 patients with pulmonary hamartoma, 14 lesions were found, of which 4 exhibited calcification. The mean diameter and SUVmax were 1.7±0.8 cm and 1.5±0.6, respectively, and there was a significant correlation between the size and SUVmax (r= 0.625, r 2 = 0.391, P<0.05). Although there was no significant difference between the size of PSH and pulmonary hamartoma (P>0.05), the SUVmax of PSH was significantly higher than that of pulmonary hamartoma (P<0.05). Moreover, the SUVmax of 1.95 was applied as a cutoff for the diagnosis of PSH, and the resulting sensitivity and specificity for PET/CT to differentiate PSH from pulmonary hamartoma were 83.3 and 78.6%, respectively. Although the morphological features were not specific, PSH showed significantly higher FDG accumulation than pulmonary hamartoma on PET/CT imaging, which may aid the differential diagnosis. Further studies with larger populations are warranted to confirm these study results.

show abstract

“…It is generally considered a benign malady, but several cases with lymph node metastasis or multifocal pulmonary involvement have been reported (4,5). The origin of PSH is controversial; however, recent studies on the expression levels of estrogen receptors and the markers of type II pneumocytes, such as TTF-1, MUC1, Thomsen- Table V.…”

Section: Discussionmentioning

confidence: 99%

“…Histopathological diagnosis can be confirmed through the presence of a mixture of the 4 major histological patterns and through the distinctive cellular components (surface-lining cuboidal and stromal-pale tumor cells) found within a single tumor (1)(2)(3). Several cases with lymph node metastasis or multifocal lung involvement have been reported (4,5), but did not have a bad prognosis. It is therefore thought that the nature of this tumor is between benign and malignant.…”

Section: Introductionmentioning

confidence: 99%

Increased expression of matrix metalloproteinase 9 and tubulin-α in pulmonary sclerosing hemangioma

Cho

Jin²,

Kim

et al. 2007

Oncol Rep

View full text Add to dashboard Cite

Abstract. Pulmonary sclerosing hemangioma (PSH) is relatively rare and is usually considered a benign tumor because of its slow growth and solitary characteristics. However, several cases with lymph node metastasis have been reported, and its pathogenesis has not been fully elucidated. Three sets of PSH specimens from the Korea Lung Tissue Bank, obtained with IRB approval, were analyzed through the construction of an oligo-microarray that contained about 32,000 genes. The resulting data were confirmed by real-time RT-PCR. Protein expression levels were checked by performing immunohistochemistry (IHC) and immunoblot analysis. In the 3 specimens of PSH tissues, 72 of the 32,000 genes were commonly found up-regulated and 290 were commonly found down-regulated as compared to non-tumor tissues from each patient. Paraffin-embedded tissues from 11 cases were used to confirm the expression of matrix metalloproteinase 9 (MMP-9) and tubulin-α proteins in the non-tumor and PSH tissues via IHC. In addition, the upregulation of protein expression was confirmed by immunoblot analysis. As expected, in all cases MMP-9 and tubulin-α were expressed at significantly higher levels in the PSH than in the non-tumor tissues. This is the first report on a study of the whole genome of PSH. Increased expression of MMP-9 could induce the metastatic ability of PSH and tubulin-α might be responsible for the sclerotic character of this disease. The results of this study will be useful in helping to understand and effectively manage patients suffering from PSH.

show abstract

Pulmonary Sclerosing Hemangioma with Pulmonary Metastasis

Cited by 32 publications

References 5 publications

Pulmonary sclerosing hemangioma with pleural dissemination: Report of a case

Pulmonary sclerosing hemangioma with pleural dissemination: Report of a case

18F‑FDG PET/CT characteristics of pulmonary sclerosing hemangioma vs. pulmonary hamartoma

Increased expression of matrix metalloproteinase 9 and tubulin-α in pulmonary sclerosing hemangioma

Contact Info

Product

Resources

About